Anti-inflammatory activity of azithromycin as measured by its NF-KB inhibitory activity

Ocular Immunology and Inflammation

Volumn 18, Issue 1, 2010, Pages 32-37

  Cheung, Paul S ^a   Si, Erwin C ^a   Hosseini, Kamran ^b  

^a InSite Vision   (United States)

^b InSite Vision   (United States)

Author keywords

Anti inflammatory; Azithromycin; Glucocorticoid; Macrolide; NF KB

Indexed keywords

ANTIINFLAMMATORY AGENT; AZITHROMYCIN; DEXAMETHASONE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEPHARITIS; CONTROLLED STUDY; DOSE RESPONSE; FLUORESCENCE ANALYSIS; HUMAN; IC 50;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZITHROMYCIN; CELL LINE, TUMOR; DEXAMETHASONE; HUMANS; HYDROCORTISONE; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76749149078     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273940903359725     Document Type: Article

References (29)

1. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of deliver and release at sites of infection. Antimicrob Agents Ch. 1989;33:277-282.
2. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Ch. 1990;25(Suppl):S73-S82.
3. Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Ch. 1996;40:75-79.
4. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother. 1999;33:218-228.
5. Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit. 2006;28:219-225.
6. Kuper H, Wormald R. Topical azithromycin: New evidence. BJO, 2007;91:556-567.
7. Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DC. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ. 2001;79:632-640.
8. Luchs J. Efficacy of topical azithromycin ophthalmic solution in the treatment of posterior blepharitis. Adv Ther. 2008;25:858-870.
9. Gray GC, McPhate DC, Leinonen M, et al. Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease. Clin Infect Dis. 1998;26:103-110.
10. Guven M, Bulut Y, Sezer T, Aladag I, Eyibilen A, Etikan I. Bacterial etiology of acute otitis media and clinical efficacy of amoxicillin-clavulanate versus azithromycin. Int J Pediatr Otorhinolaryngol. 2006;70:915-923.
11. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MSA, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34-40.
12. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566-570.
13. Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in pseudomonas endobronchial infection. Am J Respir Crit Care Med. 2004; 170:1331-1339.
14. Tkalevi VI, Bošnjak B, Hrvai B, et al. Antiinflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol. 2006;539:131-138.
15. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12:141-179.
16. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10: 405-455.
17. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-?B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62:483-488.
18. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Ch. 2007;51:975-981.
19. Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol. 1993;45(Suppl 1):S3-S7.
20. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcription activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
21. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NFkappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
22. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: A class of potent immunomodulators. Int J Antimicrob Agents 2008;31:12-20.
23. Nakao S, Hata Y, Miura M, Noda K, Kimura YN, et al. Dexamethasone inhibits interleukin -1-induced corneal neovascularization: Role of nuclear factor-?B-activated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007;171:1058-1065.
24. Aghai ZH, Kumar S, Farhath S, et al. Dexamethasone suppresses expression of nuclear factor-kappaB in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress. Pediatr Res. 2006;59:811-815.
25. Langhoff E and Ladefoged J. Relative immunosuppressive potency of various corticosteroids measured in vitro. Eur J Clin Pharmacol. 1983;25:459-462.
26. Cantrill HL, Waltman SR, Palmberg PF, Zink HA, Becker B. In vitro determination of relative corticosteroid potency. J Clin Endocrinol Metab. 1975;40:1073-1077.
27. Yamasawa H, Oshikawa K, Ono S, Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Resp Cell Mol Biol. 2004;30:569-575.
28. Bowman LM, Si E, Pang J, Archibald R, Friedlaender M. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther. 2009;25:133-139.
29. Crean C, Vittitow JL, Zink RC, Richards L, Verhoeven RS. Comparison of AzaSite and azithromycin 1% for bacterial conjunctivitis. Abstract presented at the American Society of Cataract and Refractive Surgery (ASCRS) 2008 Annual Meeting, Chicago, Illinois, USA, April 4-9, 2008.